INNATE PHARMA news, videos and press releases
For more news please use our advanced search feature.
INNATE PHARMA - More news...
INNATE PHARMA - More news...
- Innate Pharma to Participate in Upcoming Investor Conference
- Innate Pharma to Participate in Upcoming Investor Conference
- First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
- First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
- Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
- Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
- First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
- Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
- Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
- Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
- Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
- Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
- Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
- Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
- SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
- Innate Pharma: SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
- Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
- Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
- Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
- Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
- Innate Pharma to Participate in Upcoming Investor Conferences
- Innate Pharma to Participate in Upcoming Investor Conferences
- Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
- Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
- Outcome of Innate Pharma’s 2023 Annual General Meeting
- Outcome of Innate Pharma’s 2023 Annual General Meeting
- Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
- Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
- Number of shares and voting rights of Innate Pharma as of May 1, 2023
- Number of shares and voting rights of Innate Pharma as of May 1, 2023